选择性雌激素受体共价拮抗剂治疗ERα野生型与突变型乳腺癌的发现
在内分泌治疗复发患者中,高达30%可检出导致耐药的相关ERα突变,且耐药转移灶仍依赖ERα信号。研究通过药物发现获得H3B-5942,其靶向Cys530共价灭活野生型与突变型ERα并诱导独特拮抗构象,属于选择性雌激素受体共价拮抗剂(SERCA)。体外对比显示其对ERα野生型与突变型细胞系的拮抗活性增强;体内在ERα野生型与ERαY537S异种移植模型中单药抗肿瘤活性显著且优于氟维司群;与CDK4/6或mTOR抑制剂联合可进一步提升效力。
要点
- H3B-5942靶向Cys530共价灭活野生型与突变型ERα,属于SERCA类口服拮抗剂。
- 体外对ERα野生型与突变型细胞系的拮抗活性优于标准治疗与实验药物。
- 体内在ERα野生型与ERαY537S模型中单药活性优于氟维司群,联合CDK4/6或mTOR抑制剂可增强效力。
核心结论
- H3B-5942是口服SERCA,可共价灭活野生型与突变型ERα,体外与体内活性优于标准治疗药物。
- 在ERα野生型与ERαY537S异种移植模型中,H3B-5942单药抗肿瘤活性显著且优于氟维司群。
- H3B-5942与CDK4/6或mTOR抑制剂联合可在ERα野生型与突变型细胞系和/或肿瘤模型中进一步提升效力。
研究设计与样本
- 研究为药物发现与临床前研究,通过药物发现工作识别H3B-5942。
- 体外比较H3B-5942与标准治疗及实验药物在ERα野生型与突变型细胞系中的拮抗活性。
- 体内在代表ERα野生型与ERαY537S乳腺癌的异种移植模型中评估单药抗肿瘤活性。
主要发现
- 在内分泌治疗复发患者中,高达30%可检出导致耐药的ERα突变。
- H3B-5942靶向Cys530共价灭活野生型与突变型ERα,并强制形成独特拮抗构象。
- 体外比较显示H3B-5942在ERα野生型与突变型细胞系中拮抗活性增强。
- 体内H3B-5942在ERα野生型与ERαY537S异种移植模型中单药抗肿瘤活性显著且优于氟维司群。
- H3B-5942与CDK4/6或mTOR抑制剂联合可在ERα野生型与突变型细胞系和/或肿瘤模型中进一步提升效力。
关键数值与推荐
- 在内分泌治疗复发患者中,高达30%可检出导致耐药的ERα突变。
- H3B-5942靶向ERα的Cys530并共价灭活野生型与突变型ERα。
- H3B-5942属于选择性雌激素受体共价拮抗剂(SERCA)类口服拮抗剂。
临床怎么用
- 针对内分泌治疗耐药且ERα突变仍依赖ERα信号的乳腺癌,SERCA类口服拮抗剂是潜在治疗方向。
- 临床前提示H3B-5942可单药使用,并可与CDK4/6或mTOR抑制剂联合以提升效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-resistant breast cancer metastases continue to be dependent on ERα signaling, there remains a critical need to develop the next generation of ERα antagonists that can overcome aberrant ERα activity. Through our drug-discovery efforts, we identified H3B-5942, which covalently inactivates both wild-type and mutant ERα by targeting Cys530 and enforcing a unique antagonist conformation. H3B-5942 belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists (SERCA). In vitro comparisons of H3B-5942 with standard-of-care (SoC) and experimental agents confirmed increased antagonist activity across a panel of ERαWT and ERαMUT cell lines. In vivo, H3B-5942 demonstrated significant single-agent antitumor activity in xenograft models representing ERαWT and ERαY537S breast cancer that was superior to fulvestrant. Lastly, H3B-5942 potency can be further improved in combination with CDK4/6 or mTOR inhibitors in both ERαWT and ERαMUT cell lines and/or tumor models. In summary, H3B-5942 belongs to a class of orally available ERα covalent antagonists with an improved profile over SoCs.Significance: Nearly 30% of endocrine therapy-resistant breast cancer metastases harbor constitutively activating mutations in ERα. SERCA H3B-5942 engages C530 of both ERαWT and ERαMUT, promotes a unique antagonist conformation, and demonstrates improved in vitro and in vivo activity over SoC agents. Importantly, single-agent efficacy can be further enhanced by combining with CDK4/6 or mTOR inhibitors. Cancer Discov; 8(9); 1176-93. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 1047.
引用
- Puyang X, Furman C, Zheng GZ, et al. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. Cancer Discov. 2018. PMID: 29991605. doi:10.1158/2159-8290.CD-17-1229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。